spacer
home > pmps > summer 2019 > a cold case
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

A Cold Case

Patient safety will always be the top priority of every clinical trial. Therefore, it is vital that the investigational medicine dispensed to the patient is pure, safe, and effective no matter what challenges are presented by packaging, storage, and distribution requirements.

Many medicines have a stringent stability profile, where the acceptable temperature range in which the drug must be stored and distributed is strictly dictated to ensure the product remains safe and effective. This is becoming the norm rather than the exception, with large molecules and biologic medicines now playing a more prominent role in clinical development. Therefore, ensuring the biologics are optimally safe and effective is often an issue of sustaining the product at very specific temperatures and maintaining these requisites despite what can be differing, and even extreme, environmental conditions.

To control the temperature conditions of the drug at every step in the supply chain, it is critical that trial sponsors consider a range of factors. From the point in time that the drug is first manufactured through to the end delivery to the patient, it will be exposed to a multitude of environments during its lifecycle. Stages of this will include initial packaging, storage at the distribution facility, clinical site transportation and storage, and distribution to the patient.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Brian Keesee, Vice President and General Manager of PCI’s Global Clinical Operations and Supply, has spent his entire career in the pharma industry. In his current role, Brian is responsible for global clinical operations and project management, including PCI’s stateof- the-art packaging and distribution facilities located in Rockford, US, and Bridgend, UK.
spacer
Brian Keesee
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Signant Health Enhances Audit Trail Reporting Capabilities in TrialMax® to Improve eCOA Data Integrity Monitoring

PHILADELPHIA, PA – 29th January, 2020: Signant Health has announced new audit trail reviewing and reporting functionality today for its electronic clinical outcome assessment (eCOA) and remote sensor platform, TrialMax®.
More info >>

White Papers

eSource: Reducing Site Workload for Better, Faster, Safer Clinical Trials

Clinical Ink

Unlike traditional electronic data capture (EDC), SureSource, Clinical Ink’s eSource platform, was designed from the beginning to minimize clinical trial complexity for site users. A Site Impact Survey provides scientific evidence regarding the impact of SureSource from 517 site users. Results confirm it significantly reduces workload, lessens queries, and improves data quality compared to paper and EDC. In this white paper, we quantitatively evaluate survey outcomes, provide qualitative feedback from survey respondents, and highlight the observed benefits of SureSource for transforming clinical research.
More info >>

 
Industry Events

Clinical Trial Supply Europe

11-12 March 2020, Madrid, Spain

The 21st annual edition promises to grow on the success of 2019’s excellent conference which saw delegates from Europe’s largest pharmaceutical companies and biotech innovators come together to discuss, debate and unpack the latest trends in clinical supply chain innovation. 2020 will offer delegates the opportunity to address the growing need for agility within the supply chain in response to increasingly complex trial demands. With a stream dedicated to supply operations and another to innovative uses of technology in the supply chain, delegates will get the chance to gain practical take-aways that they can apply to their own studies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement